Isobaric tagging for relative and absolute quantitation (iTRAQ). Myofibroblast CM was concentrated to 500 µl, and 80 g protein was precipitated in cold acetone, resuspended in 0.5M triethylammonium bicarbonate (TEAB) in 0.1% SDS. Samples were reduced with 2µl 50mM tris-(2-carboxyethyl) phosphine (TCEP) at 60
o C for one hour and alkylated with 1µl 200mM methyl methanethiosulfonate (MMTS) for 10 min at room temperature Myofibroblasts were lysed directly in TEAB/SDS. Samples (100g) were labelled using the 4-plex iTRAQ® kit (AB SCIEX, Foster City, CA, USA) according to manufacturer's instructions. Labelled samples were pre-fractionated using a PolyLC PolySULFOETHYL A (4.6 x 200mm i.d.) cation exchange (CEX) column using an Agilent 1100 HPLC system (Agilent Technologies, Santa Clara, CA, USA). Samples were then analysed using an LC Packings Ultimate nano-LC system run in-line with a QStar Pulsar i mass spectrometer (AB Sciex). Protein identification and quantification were performed using the ProteinPilot TM v3.0.1 software (AB Sciex). The Paragon algorithm was selected as the default search program, with the digestion agent set as trypsin and cysteine modification as methyl methanethiosulfonate. Proteins were reported based on the assignment of at least two tryptic peptides with a confidence >95%, or on the assignment of one tryptic peptide with a confidence >99% and a local FDR calculated using the PSPEP algorithm of <1%. Proteins exhibiting a differential abundance in CAMs vs ATMs were calculated only on the assignment of at least two tryptic peptides using a Pro Group™ algorithm of ProteinPilot™.
When comparing groups of patients, proteins that were identified in >80% in one of the groups were used in the analysis. Cell extracts in RIPA buffer were assayed using the DC Protein Assay (BioRad). Samples were reduced by addition of DTT to a final concentration of 100mM and processed using the method described by Wiśniewski et al (1) . Briefly, up to 100µg of protein was loaded onto
Amicon Ultra 10K centrifugal filters (Millipore), together with 200µL buffer UA (8M urea in 0.1M Tris/HCl, pH8.5) and centrifuged at 14,000 x g for 40 min, followed by a wash with a further 200µL buffer UA. Proteins were alkylated by addition of iodoacetamide to a final concentration of 50mM in buffer UA. Samples were mixed for 1min, incubated at room temperature for 5minutes, and centrifuged for 30 min. This was followed by two washes of 100µL buffer UA, then two washes of 100µL 50mM ammonium bicarbonate. Proteins were then digested by addition of 40µL 0.05µg/µL sequencing grade trypsin in ammonium bicarbonate, and incubated for 18 h at 37 o C. Digested peptides were collected in a fresh collection tube by centrifugation at 14,000 x g for 10 min, followed by a further elution wash with 50µL 0.5M NaCl. Samples were then desalted using C18 ZipTips (Millipore), dried, and resuspended in 20µL 3% acetonitrile, 0.1% formic acid.
Samples were analysed on a Nano-Acquity (Waters) reverse phase HPLC system in-line with an LTQ Orbitrap Velos (Thermo). SILAC data were searched and analysed using MaxQuant 1.1.1.36 (2) against the human IPI database v3.68 using the recommended default settings. Oxidation (M) and acetylation (protein N-term) were set as variable modifications, and carbamidomethylation (C) was set as a fixed modification. The first search function was enabled, MS/MS tolerance set to 0.5Da and the number of top peaks per 100Da set to 6. The data were also searched against a database of known contaminants. For identification, both the peptide and protein FDRs were set to 1%. For quantification, the 'filter labelled amino acids' box was unchecked, both razor and unique peptides selected for quantification and the minimum ratio count for quantification set to 1.
